Amalus Therapeutics
0803.929.268 · rovalta.com · 24/09/2026
Amalus Therapeutics
Company — Opening of bankruptcy.
Financial year 2024 · Closed on 31/12/2024
Overview
Identity
Source · BCE/KBOAmalus Therapeutics is a Private limited company incorporated in 2023. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Gent. It employs on average 1,6 ETP workers (FTE).
- Legal situation
- Opening of bankruptcy
- BCE/KBO no. / VAT
- BE 0803.929.268
- Incorporation
- 13/07/2023
- Legal form
- Private limited company
- Registered office
- Technologiepark-Zwijnaarde 82
9052 Gent · FlandreSee on map - Contributed capital
- 10 000,00 €
- Latest accounts
- 31/12/2024
- Average workforce
- 1,6 ETP
Joint committees (1)
- 2000
Financials
Source · NBB, 1 filingTrend over 1 financial year
| 2024 | |
|---|---|
| Income statement | |
| Gross margin | 111,4 k € |
| EBITDA | -4,6 k € |
| Operating result | -330,3 k € |
| Net result | -341,7 k € |
| Balance sheet | |
| Equity | -331,7 k € |
| Total assets | 160,1 k € |
| Cash | 123,4 k € |
| Debts | 491,8 k € |
| Other | |
| Workforce | 1,6 ETP |
Board of directors
Source · NBB, accounts to 31/12/20243 active
Active mandates
Other companies at this address
Technologiepark-Zwijnaarde 82 9052 Gent| Company | CBE no. |
|---|---|
APCOR R&M● Active | 0600.952.909 |
Ardoyen● Active | 0875.102.821 |
AVROXA● Active | 0687.774.936 |
Benebiose● Active | 0784.521.548 |
BioNeering● Active | 0807.194.309 |
CONTREL EUROPE● Active | 0426.204.637 |
CRODEON TECHNOLOGIES● Active | 0642.754.761 |
Cryptobiotix● Active | 0762.565.104 |
Gulliver Biomed● Active | 0692.527.837 |
ImplicitMeasures.com● Bankrupt | 0657.989.701 |
Inbiose● Active | 0534.887.593 |
| 0440.054.752 | |
INNOVATIVE PHARMACEUTICS● Active | 0883.574.582 |
Inspect● Active | 0645.950.417 |
INVIBES ADVERTISING● Active | 0836.533.938 |
KYTOS● Active | 0768.755.286 |
Lares Solutions● Active | 1015.346.906 |
| 0755.350.975 | |
| 0742.910.132 | |
| 0667.765.816 |
Financials
Full financial information
Source · NBB| 2024 | |
|---|---|
| Type of account | Abridged model |
| Start of the financial year | 13/07/2023 |
| Closing of the financial year | 31/12/2024 |
| Length of the financial year | 18 months |
| Filing date | 07/07/2025 |
| General meeting | 06/06/2025 |
| Currency of the financial year | EUR |
| NBB quality label | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 1 filing| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2024 | 06/06/2025 | 07/07/2025 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20243 active
Active mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Other17/07/2023RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 2024-341,7 k €
- 13/07/2023IncorporationPrivate limited company